LEADER 04665nam 2201105z- 450 001 9910566457403321 005 20220506 035 $a(CKB)5680000000037807 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81056 035 $a(oapen)doab81056 035 $a(EXLCZ)995680000000037807 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNew Therapies of Liver Diseases 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (236 p.) 311 08$a3-0365-3859-3 311 08$a3-0365-3860-7 330 $aIn this Special Issue of the journal, advancements in the treatment of liver diseases are illustrated by international experts in the field. New treatment options for primary biliary cirrhosis and, hopefully, primary sclerosing cholangitis are discussed. Up-to-date pharmacological therapy for preventing liver cirrhosis decompensation and treating acute-on-chronic liver failure is highlighted. Furthermore, new treatments for cholangiocarcinoma, based on biological and tissue markers, will be available in the near future, aiming to surpass the current unsatisfactory results of traditional therapies. Immunotherapy has been applied to hepatocellular carcinoma (HCC). The new first-line treatment, combining atezolizumab plus bevacizumab for HCC in the intermediate and advanced stages, will allow for an increase in patient survival in the near future. Liver transplantation (LT) remains the preferred treatment for many patients with end-stage liver diseases and HCC. The selection criteria for LT in patients with HCC moved from morphological to dynamic criteria, such as those derived from the assessment of tumor responses to locoregional and/or systemic treatments before transplantation. This allowed many patients who would have been excluded from a transplantation with the old selection criteria to access one. Finally, a very interesting issue regarding new indications for liver transplantation is illustrated. 606 $aPublic health and preventive medicine$2bicssc 610 $aacute-on-chronic liver failure 610 $aacute-on-chronic liver failure (ACLF) 610 $aalcoholic hepatitis 610 $aalpha-fetoprotein 610 $aammonia 610 $aanti-mineralocorticoids 610 $aantivirals 610 $aascites 610 $aautoantibodies 610 $ableeding 610 $acholangiocarcinoma 610 $acirrhosis 610 $acirrhotic ascites 610 $aclinical trials 610 $acolorectal cancer metastases 610 $adecompensated cirrhosis 610 $adecompensation 610 $aeffective hypovolemia 610 $aFarnesoid X Receptor (FXR) agonist 610 $afunctional cure 610 $afurosemide 610 $aHBV 610 $aHDV 610 $ahepatocellular carcinoma 610 $ahuman albumin 610 $ahumoral response 610 $aimmunosuppressant 610 $aimmunotherapy 610 $ainfection 610 $aliver cancer 610 $aliver injury 610 $aliver transplantation 610 $aliver transplantation (LT) 610 $aloop diuretics 610 $aMilan criteria 610 $an/a 610 $anon-selective beta-blockers 610 $aPan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists 610 $apharmacology 610 $aportal hypertension 610 $aportal-systemic shunt 610 $aprimary biliary cholangitis 610 $aprimary biliary cholangitis (PBC) 610 $aprimary sclerosing cholangitis (PSC) 610 $areal-world 610 $arifaximin 610 $aSARS-CoV-2 610 $asecond line therapy 610 $asolid organ transplantation 610 $astatins 610 $asurvival 610 $asurvival rate 610 $asystemic treatment 610 $atargeted therapy 610 $aTIPS 610 $atolvaptan 610 $atreatment response 610 $aunresectable hepatocellular carcinoma 610 $aursodeoxycholic acid 610 $aursodeoxycholic acid (UDCA) 610 $avaccination 610 $avaptans 610 $avarices 610 $avigilance 615 7$aPublic health and preventive medicine 700 $aToniutto$b Pierluigi$4edt$01319547 702 $aToniutto$b Pierluigi$4oth 906 $aBOOK 912 $a9910566457403321 996 $aNew Therapies of Liver Diseases$93033951 997 $aUNINA